M&A Deal Summary

AstraZeneca Acquires Omthera Pharmaceuticals

On July 18, 2013, AstraZeneca acquired life science company Omthera Pharmaceuticals for 323M USD

Acquisition Highlights
  • This is AstraZeneca’s 6th transaction in the Life Science sector.
  • This is AstraZeneca’s 13th largest (disclosed) transaction.
  • This is AstraZeneca’s 4th transaction in the United States.
  • This is AstraZeneca’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2013-07-18
Target Omthera Pharmaceuticals
Sector Life Science
Buyer(s) AstraZeneca
Deal Type Add-on Acquisition
Deal Value 323M USD

Target

Omthera Pharmaceuticals

Bedminster Township, New Jersey, United States
Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease.

Search 202,465 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 7 of 20
Sector (Life Science) 6 of 18
Type (Add-on Acquisition) 6 of 15
State (New Jersey) 1 of 1
Country (United States) 4 of 10
Year (2013) 2 of 2
Size (of disclosed) 13 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-28 Pearl Therapeutics

Redwood City, California, United States

Pearl was founded in 2006, with a mission to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD). The product candidates currently being developed are based on the simple and widely prescribed metered-dose inhaler (MDI) dosage form. Company scientists have invented a novel cosuspension formulation technology for use with MDIs that enables efficient targeting and distribution of drug to the lungs.

Buy $1.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-11-19 AstraZeneca - VIMOVO

United States

AstraZeneca - VIMOVO(R) is approved in the U.S. to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with NSAIDs.

Sell -
Mergr

Product

Company

Legal